Challenges to conducting a clinical trial of combination therapy of colistin and rifampicin for extensively drug-resistant acinetobacter baumannii

Clinical Infectious Diseases

Volumn 58, Issue 1, 2014, Pages 141-142

  Huang, David B ^a   Pastagia, Mina ^b   Chiang, Tom ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM DERIVATIVE; COLISTIN; MEROPENEM; RIFAMPICIN; TIGECYCLINE;

ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CLINICAL TRIAL (TOPIC); DRUG MONITORING; HUMAN; LETTER; MAJOR CLINICAL STUDY; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT DURATION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; RIFAMPIN;

EID: 84891359238     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit630     Document Type: Letter

References (5)

1. Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013; 57:349-58.
2. Sheng WH, Wang JT, Li SY, et al. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn Microbiol Infect Dis 2011; 70:380-6.
3. McGovern PC,Wible M, El-Tahtawy A, Biswas PMeyer RD. All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials. Int J Antimicrob Agents 2013; 41:463-7.
4. Forrest GN, Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev 2010; 23:14-34.
5. Itani KM, Dryden MS, Bhattacharyya H, Kunkel MJ, Baruch AM, Weigelt JA. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and softtissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2010; 199:804-16.